HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Topical tacrolimus neither prevents nor abolishes ultraviolet-induced erythema.

Abstract
A dose- and vehicle-controlled study on the pretreatment and posttreatment effect of 0.1% tacrolimus ointment on erythema induced by solar-simulated ultraviolet (UV) radiation was performed. Surprisingly, comparisons of clinical erythema scores and colorimetric data obtained 24 and 72 hours after UV exposure did not reveal significant differences between the control, tacrolimus, and vehicle preirradiation and postirradiation treated sites (P > .05). Our data strongly indicate that topical tacrolimus neither prevents nor abolishes UV-induced erythema in a clinical meaningful degree.
AuthorsThilo Gambichler, Nordwig S Tomi, Georg Moussa, Julia Huyn, Heinrich Dickel, Peter Altmeyer, Alexander Kreuter
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 55 Issue 5 Pg. 882-5 (Nov 2006) ISSN: 1097-6787 [Electronic] United States
PMID17052498 (Publication Type: Controlled Clinical Trial, Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Tacrolimus
Topics
  • Administration, Topical
  • Adult
  • Anti-Inflammatory Agents (administration & dosage, therapeutic use)
  • Dose-Response Relationship, Drug
  • Erythema (drug therapy, etiology, prevention & control)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Tacrolimus (administration & dosage, therapeutic use)
  • Treatment Failure
  • Ultraviolet Rays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: